HalozymeHALO
Market Cap: $7.5B
About: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Employees: 373
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
451% more call options, than puts
Call options by funds: $19.7M | Put options by funds: $3.58M
175% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 11 (+7) [Q2]
155% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 31
27% more capital invested
Capital invested by funds: $5.05B [Q1] → $6.39B (+$1.35B) [Q2]
12% more funds holding
Funds holding: 405 [Q1] → 453 (+48) [Q2]
2% more repeat investments, than reductions
Existing positions increased: 160 | Existing positions reduced: 157
1.74% less ownership
Funds ownership: 97.7% [Q1] → 95.96% (-1.74%) [Q2]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
11 analyst ratings
Benchmark Robert Wasserman 50% 1-year accuracy 22 / 44 met price target | 1%upside $60 | Buy Reiterated | 8 Aug 2024 |
HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 58 / 119 met price target | 10%upside $65 | Buy Reiterated | 8 Aug 2024 |
TD Cowen Brendan Smith 67% 1-year accuracy 2 / 3 met price target | 10%upside $65 | Buy Maintained | 7 Aug 2024 |
Morgan Stanley Vikram Purohit 80% 1-year accuracy 4 / 5 met price target | 8%upside $64 | Overweight Maintained | 7 Aug 2024 |
JP Morgan Jessica Fye 62% 1-year accuracy 23 / 37 met price target | 12%downside $52 | Overweight Maintained | 6 Aug 2024 |
Financial journalist opinion
Based on 9 articles about HALO published over the past 30 days